Literature DB >> 33499504

Recombinant Human MG53 Protein Protects Against Alkaline-Induced Corneal Injuries in Mice.

Owen Guo1,2, Brent Ju3,2, McKinley H Shawver2, Bingchuan Geng2, Siqi Wei2, Terriah Early2, Frank Yi2, Tao Tan2,4, Heather L Chandler5, Jianjie Ma2,1, Hua Zhu2,1.   

Abstract

INTRODUCTION: The current study was designed to test the potential role of recombinant human MG53 (rhMG53) protein on protecting against alkaline-induced corneal injury in mice.
MATERIALS AND METHODS: A round filter paper with 2-mm diameter was soaked in 1 mol/L of NaOH solution. The mouse alkaline injury was generated by placing the filter paper directly on the cornea for 30 seconds and washed with 30-mL saline; 10 µL of rhMG53 solution (20 µg/mL) or saline control was topically administrated on the mouse corneas (twice per day for 10 days). Re-epithelialization was measured by fluorescein staining and imaged by a slit lamp equipped with a digital camera. Clinical neovascularization and opacity scores were measured every day after injury. Ten days after injury, mice were sacrificed and corneas were dissected out for flat mount staining of CD31 for neovascularization.
RESULTS: MG53 was present in both dog aqueous humor and human tears. mg53-/- corneas were more susceptible to alkaline-induced corneal injury. Topical treatment of rhMG53 improved re-epithelialization, suppressed neovascularization, and fibrosis induced by alkaline injury.
CONCLUSIONS: rhMG53 may be an effective means to treat corneal wounding. © The Association of Military Surgeons of the United States 2021. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33499504      PMCID: PMC7980491          DOI: 10.1093/milmed/usaa357

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  18 in total

Review 1.  New therapeutic approaches in the treatment of diabetic keratopathy: a review.

Authors:  Hamdy Abdelkader; Dipika V Patel; Charles Nj McGhee; Raid G Alany
Journal:  Clin Exp Ophthalmol       Date:  2011-04-04       Impact factor: 4.207

2.  Recombinant MG53 protein modulates therapeutic cell membrane repair in treatment of muscular dystrophy.

Authors:  Noah Weisleder; Norio Takizawa; Peihui Lin; Xianhua Wang; Chunmei Cao; Yan Zhang; Tao Tan; Christopher Ferrante; Hua Zhu; Pin-Jung Chen; Rosalie Yan; Matthew Sterling; Xiaoli Zhao; Moonsun Hwang; Miyuki Takeshima; Chuanxi Cai; Heping Cheng; Hiroshi Takeshima; Rui-Ping Xiao; Jianjie Ma
Journal:  Sci Transl Med       Date:  2012-06-20       Impact factor: 17.956

Review 3.  Translational research in corneal epithelial wound healing.

Authors:  Teruo Nishida
Journal:  Eye Contact Lens       Date:  2010-09       Impact factor: 2.018

Review 4.  Eye injuries on the battlefields of Iraq and Afghanistan: public health implications.

Authors:  Adrienne B Ari
Journal:  Optometry       Date:  2006-07

5.  MG53-mediated cell membrane repair protects against acute kidney injury.

Authors:  Pu Duann; Haichang Li; Peihui Lin; Tao Tan; Zhen Wang; Ken Chen; Xinyu Zhou; Kristyn Gumpper; Hua Zhu; Thomas Ludwig; Peter J Mohler; Brad Rovin; William T Abraham; Chunyu Zeng; Jianjie Ma
Journal:  Sci Transl Med       Date:  2015-03-18       Impact factor: 17.956

6.  Polymerase transcriptase release factor (PTRF) anchors MG53 protein to cell injury site for initiation of membrane repair.

Authors:  Hua Zhu; Peihui Lin; Gejing De; Kyoung-han Choi; Hiroshi Takeshima; Noah Weisleder; Jianjie Ma
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

7.  Cardioprotection of recombinant human MG53 protein in a porcine model of ischemia and reperfusion injury.

Authors:  Jianxun Liu; Hua Zhu; Yongqiu Zheng; Zhaobin Xu; Lei Li; Tao Tan; Ki Ho Park; Jincai Hou; Cuixiang Zhang; Dan Li; Ran Li; Zhenguo Liu; Noah Weisleder; Desheng Zhu; Peihui Lin; Jianjie Ma
Journal:  J Mol Cell Cardiol       Date:  2014-12-20       Impact factor: 5.000

8.  MG53 permeates through blood-brain barrier to protect ischemic brain injury.

Authors:  Yonggang Yao; Bo Zhang; Hua Zhu; Haichang Li; Yu Han; Ken Chen; Zhen Wang; Jing Zeng; Yukai Liu; Xinquan Wang; Yu Li; Duofen He; Peihui Lin; Xinyu Zhou; Ki Ho Park; Zehua Bian; Zhishui Chen; Nianqiao Gong; Tao Tan; Jingsong Zhou; Meng Zhang; Jianjie Ma; Chunyu Zeng
Journal:  Oncotarget       Date:  2016-04-19

9.  MG53 promotes corneal wound healing and mitigates fibrotic remodeling in rodents.

Authors:  Heather L Chandler; Tao Tan; Chunlin Yang; Anne J Gemensky-Metzler; Rita F Wehrman; Qiwei Jiang; Cornelia M W Peterson; Bingchuan Geng; Xinyu Zhou; Qiang Wang; Denis Kaili; T M Ayodele Adesanya; Frank Yi; Hua Zhu; Jianjie Ma
Journal:  Commun Biol       Date:  2019-02-20

10.  Treatment of acute lung injury by targeting MG53-mediated cell membrane repair.

Authors:  Yanlin Jia; Ken Chen; Peihui Lin; Gissela Lieber; Miyuki Nishi; Rosalie Yan; Zhen Wang; Yonggang Yao; Yu Li; Bryan A Whitson; Pu Duann; Haichang Li; Xinyu Zhou; Hua Zhu; Hiroshi Takeshima; John C Hunter; Robbie L McLeod; Noah Weisleder; Chunyu Zeng; Jianjie Ma
Journal:  Nat Commun       Date:  2014-07-18       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.